pyrroles has been researched along with Cutaneous Mastocytosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, H; Li, T; Robinson, WA; Schowinsky, J; Wisell, J | 1 |
| Avery, AC; Charles, JB; Clifford, CA; Ehrhart, EJ; Eickhoff, JC; Elmslie, RE; London, CA; Thamm, DH; Vail, DM; Weishaar, KM | 1 |
| Boucher, JF; Lesman, SP; Merritt, DA; Michels, GM; Yancey, MF | 1 |
2 trial(s) available for pyrroles and Cutaneous Mastocytosis
| Article | Year |
|---|---|
c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Dog Diseases; Dogs; Female; Indoles; Male; Mastocytosis, Cutaneous; Mutation; Prednisone; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrroles; Vinblastine | 2018 |
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Cross-Over Studies; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Fasting; Female; Half-Life; Indoles; Injections, Intravenous; Male; Mastocytosis, Cutaneous; Molecular Structure; Protein-Tyrosine Kinases; Pyrroles | 2010 |
2 other study(ies) available for pyrroles and Cutaneous Mastocytosis
| Article | Year |
|---|---|
Avapritinib for Cutaneous Mastocytosis.
Topics: Humans; Mastocytosis; Mastocytosis, Cutaneous; Pyrazoles; Pyrroles; Triazines | 2021 |
Cancer drug approved for dogs.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Drug Approval; Indoles; Mastocytosis, Cutaneous; Protein-Tyrosine Kinases; Pyrroles | 2009 |